Vietnam recalls Sanofi Pasteur's typhoid vaccine; Researchers take a new live vaccine approach for SARS;

 @AlisonBFierce: Inovio Pharmaceuticals, a developer of synthetic vaccines, expanded its existing license agreement with UPenn. More | Follow @AlisonBFierce

> Vaccibody landed a €2 million ($2.54 million) grant from the Norwegian Research Council's BIA program to develop a therapeutic vaccine against precancerous lesions of the cervix. Story

> Inovio Pharmaceuticals ($INO) announced that its synthetic hepatitis B therapeutic vaccine generated strong T cell responses that eliminated targeted liver cells in mice. Release

> Researchers at the University of North Carolina and Vanderbilt University are taking a new live vaccine approach for SARS. Article

> A new study examines what it would cost to vaccinate girls against HPV in low-income countries. News

And Finally... Vietnam recalled Sanofi Pasteur's typhoid vaccine. Item

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.